Literature DB >> 25641897

Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study.

Inger Jorid Berg1, Désirée van der Heijde2, Hanne Dagfinrud2, Ingebjørg Seljeflot2, Inge Christoffer Olsen2, Tore K Kvien2, Anne Grete Semb2, Sella A Provan2.   

Abstract

OBJECTIVE: To compare the risk of cardiovascular disease (CVD) in ankylosing spondylitis (AS) and population controls, and to examine the associations between disease activity and CVD risk.
METHODS: A cross-sectional study was done of patients with AS grouped according to Ankylosing Spondylitis Disease Activity Score (ASDAS) into ASDAS-high and ASDAS-low. Markers of vascular pathology, impaired endothelial function [asymmetric dimethylarginine (ADMA)], and arterial stiffness [augmentation index (AIx) and pulse wave velocity (PWV)], and traditional CVD risk factors [blood pressure, lipids, body mass index (BMI), CVD risk scores] were compared between AS and controls as well as across ASDAS-high versus ASDAS-low versus controls using ANCOVA analyses.
RESULTS: Altogether, 151 patients with AS and 134 controls participated. Patients had elevated ADMA (µmol/l) and AIx (%) compared to controls: mean difference (95% CI): 0.05 (0.03, 0.07), p < 0.001 and 2.6 (0.8, 4.3), p = 0.01, respectively. AIx increased with higher ASDAS level, p(trend) < 0.04. There were no significant group differences of PWV. BMI was higher in ASDAS-high compared to ASDAS-low (p = 0.02). Total cholesterol was lower in AS compared to controls, and lower with higher ASDAS, p(trend) = 0.02. CVD risk scores were similar across groups except for Reynolds Risk Score, where the ASDAS-high group had a significantly higher score, compared to both ASDAS-low and controls.
CONCLUSION: Elevated ADMA and AIx in AS support a higher CVD risk in AS. Elevated AIx and BMI in AS with high ASDAS indicate an association between disease activity and CVD risk. Lower total cholesterol in AS may contribute to underestimation of CVD risk.

Entities:  

Keywords:  ANKYLOSING SPONDYLITIS; CARDIOVASCULAR DISEASE; DISEASE ACTIVITY; LIPOPROTEINS

Mesh:

Substances:

Year:  2015        PMID: 25641897     DOI: 10.3899/jrheum.141018

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

1.  Association between arterial stiffness, disease activity and functional impairment in ankylosing spondylitis patients: a cross-sectional study.

Authors:  Claudiu Avram; Răzvan Gabriel Drăgoi; Horațiu Popoviciu; Mihai Drăgoi; Adina Avram; Elena Amaricăi
Journal:  Clin Rheumatol       Date:  2016-05-12       Impact factor: 2.980

2.  Spondyloarthropathies: CVD prevention and statin therapy in ankylosing spondylitis.

Authors:  Anne Grete Semb; Silvia Rollefstad
Journal:  Nat Rev Rheumatol       Date:  2016-06-30       Impact factor: 20.543

3.  Progression of atherosclerosis versus arterial stiffness with age within and between arteries in systemic lupus erythematosus.

Authors:  Paola C Roldan; Ernest R Greene; Clifford R Qualls; Wilmer L Sibbitt; Carlos A Roldan
Journal:  Rheumatol Int       Date:  2019-03-16       Impact factor: 2.631

4.  Endothelial dysfunction and increased carotid intima-media thickness in patients with spondyloarthritis without traditional cardiovascular risk factors.

Authors:  Aicha Ben Tekaya; Seif Boukriba; Ahmed Fendri; Leila Rouached; Olfa Saidane; Selma Bouden; Rawdha Tekaya; Kamel Ben Salem; Ines Mahmoud; Mizouni Habiba; Leila Abdelmoula
Journal:  RMD Open       Date:  2022-07

5.  Assessment of aortic stiffness in patients with ankylosing spondylitis using cardiovascular magnetic resonance.

Authors:  P Stefan Biesbroek; Sjoerd C Heslinga; Peter M van de Ven; Mike J L Peters; Raquel P Amier; Thelma C Konings; Christopher D Maroules; Colby Ayers; Parag H Joshi; Irene E van der Horst-Bruinsma; Vokko P van Halm; Albert C van Rossum; Michael T Nurmohamed; Robin Nijveldt
Journal:  Clin Rheumatol       Date:  2018-05-12       Impact factor: 2.980

6.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

7.  Relationship of serum osteoprotegerin with arterial stiffness, preclinical atherosclerosis, and disease activity in patients with ankylosing spondylitis.

Authors:  Münevver Serdaroğlu Beyazal; Turan Erdoğan; Aysegül Kücükali Türkyılmaz; Gül Devrimsel; Medine Cumhur Cüre; Mehmet Beyazal; Ismail Sahin
Journal:  Clin Rheumatol       Date:  2016-02-04       Impact factor: 2.980

8.  Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study.

Authors:  Jean W Liew; John D Reveille; Maria Castillo; Henna Sawhney; Benjamin S Naovarat; Susan R Heckbert; Lianne S Gensler
Journal:  J Rheumatol       Date:  2020-07-01       Impact factor: 4.666

9.  Predictors of Atherosclerosis in Ankylosing Spondylitis.

Authors:  Inderjeet Verma; Pawan Krishan; Ashit Syngle
Journal:  Rheumatol Ther       Date:  2015-08-30

10.  Determination of serum methylarginine levels by tandem mass spectrometric method in patients with ankylosing spondylitis.

Authors:  Duygu Eryavuz Onmaz; Kevser Isik; Abdullah Sivrikaya; Sedat Abusoglu; İlknur Albayrak Gezer; Gulsum Abusoglu; Fatma Humeyra Yerlikaya; Ali Unlu
Journal:  Amino Acids       Date:  2021-07-17       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.